Last 47 quarters of trend data · Healthcare · Ophthalmology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -4.93 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 27.76 | 40.98 | 44.00 | 51.06 | 36.96 | 29.75 | 29.02 | 21.00 | 23.55 | 17.25 | 20.33 | 8.20 | 4.43 | 6.63 | 7.62 | 4.13 | 6.67 | 6.76 | 7.74 | 11.66 | 17.58 |
| — | +37.8% | +51.6% | +143.2% | +57.0% | +72.5% | +42.7% | +156.2% | +431.3% | +160.1% | +166.7% | +98.4% | -33.6% | -2.0% | -1.5% | -64.6% | -62.0% | -72.8% | -84.1% | -76.5% | -21.0% | |
| P/B Ratio | 1.89 | 4.25 | 3.26 | 4.14 | 8.33 | 5.24 | 4.67 | 4.55 | 4.13 | 3.00 | 2.94 | 5.33 | 34.04 | 130.46 | 42.00 | 6.57 | 6.91 | 5.04 | 5.12 | 6.53 | 9.78 |
| — | -18.9% | -30.1% | -9.1% | +101.7% | +74.3% | +58.6% | -14.6% | -87.9% | -97.7% | -93.0% | -19.0% | +392.7% | +2487.4% | +720.4% | +0.8% | -29.4% | -65.2% | -70.2% | -66.0% | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | 20.60 | — | — | — | — | — | — | — | 42.52 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 87.3% | 85.1% | 87.7% | 88.0% | 87.8% | 85.6% | 88.2% | 92.8% | 89.9% | 90.8% | 91.0% | 90.6% | 90.9% | 91.4% | 90.9% | 92.8% | 91.0% | 90.6% | 90.1% | 91.0% | 89.2% |
| — | -0.6% | -0.6% | -5.2% | -2.3% | -5.8% | -3.1% | +2.4% | -1.1% | -0.6% | +0.1% | -2.3% | -0.2% | +0.9% | +0.9% | +2.0% | +2.0% | -0.1% | +2.6% | +0.3% | -3.4% | |
| Operating Margin | -521.0% | -609.3% | -865.5% | -526.5% | -472.3% | -502.6% | -597.5% | -296.1% | -298.2% | -265.1% | -214.0% | -135.5% | -127.4% | -135.5% | -168.6% | -137.6% | -180.1% | -162.4% | -135.2% | -146.6% | -160.7% |
| — | -21.2% | -44.9% | -77.8% | -58.4% | -89.6% | -179.2% | -118.6% | -134.1% | -95.7% | -26.9% | +1.5% | +29.2% | +16.6% | -24.7% | +6.2% | -12.1% | +6.0% | +50.9% | +24.9% | +32.6% | |
| Net Margin | -513.2% | -584.5% | -821.6% | -488.0% | -477.3% | -503.9% | -598.7% | -283.3% | -236.6% | -266.3% | -438.9% | -197.4% | -3.4% | -136.2% | -226.7% | -110.4% | -202.2% | -153.0% | -95.1% | -31.3% | 21.9% |
| — | -16.0% | -37.2% | -72.3% | -101.7% | -89.2% | -36.4% | -43.5% | -6814.6% | -95.5% | -93.6% | -78.8% | +98.3% | +11.0% | -138.4% | -253.0% | -1024.7% | -111.4% | -323.7% | +97.3% | +110.8% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -54.9% | -14.3% | -14.3% | -14.2% | -24.6% | -23.7% | -22.0% | -14.5% | -10.0% | -11.1% | -26.0% | -59.0% | -9.4% | -323.2% | -134.5% | -38.1% | -43.2% | -25.8% | -14.9% | -4.4% | 3.2% |
| — | +39.7% | +34.9% | +2.3% | -146.1% | -112.8% | +15.2% | +75.4% | -6.0% | +96.6% | +80.7% | -55.0% | +78.2% | -1153.8% | -799.6% | -767.3% | -1461.8% | -148.7% | -482.0% | +98.2% | +100.2% | |
| ROA | -42.0% | -11.2% | -11.5% | -10.6% | -16.1% | -15.8% | -14.8% | -10.2% | -7.2% | -8.3% | -16.4% | -14.1% | -0.4% | -16.5% | -21.8% | -10.1% | -14.6% | -10.4% | -6.4% | -1.8% | 1.2% |
| — | +29.1% | +22.4% | -3.9% | -122.3% | -90.8% | +9.6% | +27.6% | -1900.2% | +49.7% | +24.9% | -39.7% | +97.5% | -58.3% | -241.5% | -454.2% | -1330.9% | -190.6% | -616.9% | +96.2% | +110.2% | |
| ROIC | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.12 | 0.15 | 0.14 | 0.12 | 0.30 | 0.25 | 0.29 | 0.24 | 0.21 | 0.20 | 0.18 | 0.92 | 10.57 | 20.98 | 6.65 | 1.82 | 1.29 | 0.90 | 0.74 | 0.67 | 0.67 |
| — | -39.3% | -52.3% | -51.1% | +39.7% | +26.8% | +57.2% | -73.7% | -98.0% | -99.1% | -97.3% | -49.6% | +718.6% | +2221.7% | +796.4% | +171.1% | +92.0% | +24.0% | +9.4% | -12.7% | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 15.39 | 13.11 | 14.81 | 15.39 | 7.85 | 10.09 | 10.22 | 10.66 | 13.01 | 16.64 | 21.39 | 6.66 | 4.03 | 3.11 | 3.61 | 4.13 | 4.98 | 6.14 | 7.29 | 7.26 | 8.11 |
| — | +29.8% | +44.8% | +44.4% | -39.7% | -39.3% | -52.2% | +60.2% | +222.9% | +434.5% | +493.2% | +61.2% | -19.0% | -49.3% | -50.5% | -43.2% | -38.6% | -38.9% | -12.3% | -21.3% | +126.7% | |
| Quick Ratio | 15.32 | 13.03 | 14.73 | 15.32 | 7.78 | 10.02 | 10.14 | 10.59 | 12.94 | 16.55 | 21.29 | 6.59 | 3.96 | 3.04 | 3.53 | 4.07 | 4.92 | 6.08 | 7.23 | 7.22 | 8.06 |
| — | +30.0% | +45.3% | +44.7% | -39.9% | -39.4% | -52.4% | +60.7% | +226.5% | +443.6% | +503.0% | +62.1% | -19.5% | -49.9% | -51.2% | -43.7% | -38.9% | -39.2% | -12.6% | -21.5% | +128.6% | |
| Interest Coverage | -21.47 | -27.21 | -30.91 | -21.83 | -22.12 | -21.48 | -20.47 | -14.58 | -10.32 | -12.70 | -15.01 | -6.04 | 0.85 | -9.39 | -16.15 | -7.41 | -12.46 | -10.06 | -6.45 | -1.29 | 2.60 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying OCUL stock.
Ocular Therapeutix, Inc.'s current P/E is -4.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Ocular Therapeutix, Inc.'s current operating margin is -521.0%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Ocular Therapeutix, Inc.'s business trajectory between earnings reports.